CDC issues new opioid prescribing guidelines; Sanofi partnership will focus on oral-drug development; MannKind hires Amgen exec
The government agency found that more children are treated with medication than behavioral therapy.
A painkiller manufacturer said abuse-resistant formula lessens abuse, just as the FDA comes under pressure to finalize labeling guidance.
The SEC said some company drug prices can be made public, 23andMe launched an R&D division, and Public Citizen is asking the FDA to withdraw a proposal it says will undermine drug safety information.
Novartis heart failure drug's trial changed due to Alzheimer's disease concerns; Gilead appears to be stashing profits overseas; BMS releases high cure rate data for its investigational HCV combination.
The reason: higher prices and more services.
The CDC and March of Dimes Foundation are asking prescribers to discuss safer alternatives than opioid painkillers for women who may become pregnant.
The bad news: heroin-related deaths inched upwards.
The latest data shows an overall widening of the US.
It could also eat into Merck's Pneumovax sales.
Yale researchers find patients are paying more money for newer diabetes medications as they gravitate towards insulin analogs, over human synthetic and animal insulin.
A study shows that veering off the recommended vaccination schedule ups the risk for childhood seizures.
Patients have to be high-risk or Baby Boomers for coverage.
The CDC said Thursday that most of the 288 recent US measles cases were caused by un-vaccinated travelers who brought the virus home with them.
Ten percent of surveyed doctors told the Centers for Disease Control that reimbursement rates are not enough.
The drugmaker's new vaccine has more brawn, but vaccination rates among boys and girls remain low.
The government shutdown resulted in more than 16 million unread CDC emails—the government agency's ability to track illnesses has had a sharp setback.
The midnight shutdown put 800,000 government employees on leave, including those at the FDA, NIH and CDC.
The Kimberly-Clark-backed cold and flu predictor mixes Big Data, and big branding, with an individualized focus.
Biogen extend Isis relationship for six years and $100M; HHS readies healthcare reform TV push; Medivir ends hep. B clinical trial; FDA approves Celgene cancer drug; Baxter seeks Enbrel biosimilar
CDC finds that non-Medicare adults make up the majority of preventable heart attack and stroke cases; a Facebook study shows groups can influence HIV screening; and a Shire ADHD drug gets a "no" from Germany
The FDA approved GlaxoSmithKline's second quadrivalent flu vaccine, but a CVS study indicates that consumers are big fans of the vaccination, as long as they aren't the ones rolling up their sleeves.
Messaging around HIV testing now mixes individual concerns with community protection. Recent efforts, like those of the CDC and Greater than AIDS, try to make getting tested an empowering act.
Astellas teams up with Cytokinetics for muscle weakness research; ADA says lifestyle changes don't protect diabetics' hearts; AJMC talks pharmacists as diabetes counselors; and AARP helps with healthcare reform education.
Gilead combo drug clears HCV; FDA denies Xarelto expanded indication for a second time
The Million Hearts initiative just got a Spanish-language rollout, and the culturally sensitive content is starting to gain attention.
Elsevier launches a new title, FDA is holding a public hearing on opioids and chronic pain.
The FDA approved a flu vaccine that can be produced quickly, and lacks many elements that make patients skittish.
- Five things for pharma marketers to know: Wednesday, March 22, 2017
- Drugmakers target severe asthma patients with biologics, but payers raise pricing issue
- Novartis aims to bring first oral asthma drug to market in two decades
- What five different pharma marketing careers look like
- Veeva and QuintilesIMS tussle over customer reference data
- 2017 Healthcare Marketers Trend Report: All the data in one place
- Infographic: What's next for the point of care market
- Drugmakers again boost DTC spending, to $5.6 billion in 2016
- Digital IDs become focus as drugmakers seek to track doctors' behavior online
- Some CME experts remain skeptical when it comes to social media